कोशिश गोल्ड - मुक्त
Integrating design precision, turnkey excellence, and sustainable modular innovation to build a healthier tomorrow
Chronicle Pharmabiz
|November 27, 2025
The pharmaceutical facility landscape is clearly complex today.
-
The industry challenge and a holistic solution
In your view, what is the single biggest pitfall companies face when starting a major construction or expansion project?
The biggest pitfall is a lack of upfront integration. Building a modern facility isn't just construction; it must seamlessly integrate process design, utilities, automation, and rigorous regulatory compliance (like USFDA guidelines, cGMP, and Annex 1, etc.) all at once. Many issues arise simply because integration is considered late in the process, rather than from the very start, leading to fragmented execution and costly rework.
How does Pharma Access fundamentally change the traditional approach to designing and building these facilities?
We've pioneered a holistic approach we call 'Integration from the Ground Up.' We embed compliance and efficiency from the outset. By baking regulatory considerations into every phase, from conceptualization to commissioning we ensure the final facility is not only compliant but also optimized for seamless, high-performance operation.
Predictive design and quality assurance
Your team relies heavily on 'Simulation-Based Engineering.' What is the practical benefit of building a digital twin before laying the first brick?
Simulation is a powerful predictive tool. saving time, money, and compliance headaches. We build virtual replicas, a complete digital twin of process flows, HVAC systems, piping, and electrical circuits. This allows us to anticipate operational challenges and optimize system layouts virtually, drastically reducing the risk of costly field modifications. For example, we use Computational Fluid Dynamics (CFD) simulations for cleanroom design to guarantee adherence to ISO 14644 standards, calculating the precise Air Changes Per Hour (ACH):
ACH = Q x 60/V
यह कहानी Chronicle Pharmabiz के November 27, 2025 संस्करण से ली गई है।
हजारों चुनिंदा प्रीमियम कहानियों और 10,000 से अधिक पत्रिकाओं और समाचार पत्रों तक पहुंचने के लिए मैगज़्टर गोल्ड की सदस्यता लें।
क्या आप पहले से ही ग्राहक हैं? साइन इन करें
Chronicle Pharmabiz से और कहानियाँ
Chronicle Pharmabiz
US FDA fortifies alliance with Telangana DCA
A high-level delegation from the US FDA concluded a significant meeting with the DCA in Telangana, two days ago, at the DCA office in Hyderabad.
2 mins
December 11, 2025
Chronicle Pharmabiz
India exploring possibilities to expand WHO standards for Indian medicines
INDIA is looking at possibilities to expand the World Health Organisation (WHO) global benchmarking standards for medicines, in order to unify and strengthen the drug regulatory mechanism for safety, quality and efficacy of medicines sold in the country.
1 min
December 11, 2025
Chronicle Pharmabiz
Eli Lilly gets US FDA approval for Jaypirca
Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor.
1 mins
December 11, 2025
Chronicle Pharmabiz
Haryana DCA focuses on quality overhaul
THE Haryana drug control administration (DCA) is undertaking a major organizational overhaul focused on quality system upgrades and regulatory capacity building, particularly in response to the revised Schedule M norms.
2 mins
December 11, 2025
Chronicle Pharmabiz
DoC seeks inputs on trade issues faced with Japan
THE Department of Commerce (DoC), under the Union Commerce Ministry, has sought inputs from the industry on specific issues being faced in pharma trade with Japan.
1 min
December 11, 2025
Chronicle Pharmabiz
AIOCD asks traders to strictly comply with ban on 35 FDCs
THE All India Organisation of Chemists and Druggists (AIOCD) has issued an urgent internal circular to all its state and Union territory trade bodies, demanding immediate and strict compliance with the ban on 35 fixed dose combinations (FDCs).
3 mins
December 11, 2025
Chronicle Pharmabiz
US FDA approves Bristol Myers Squibb's Breyanzi
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.
2 mins
December 11, 2025
Chronicle Pharmabiz
CN Water presents AQU@Sense MB
CN Water is now combining core water-system expertise with digital assurance has launched AQU@Sense which delivers microbial test results in under 30 minutes, replacing traditional 5 to 7 days culture based methods.
1 min
December 11, 2025
Chronicle Pharmabiz
Pharma logistics sees policy push as key catalyst for growth
INDIAN pharma's logistics sector is getting major boost from emerging policy support.
2 mins
December 11, 2025
Chronicle Pharmabiz
Lack of financial aid, expertise mar MSME prospects to meet revised Sch M deadline
INDUSTRY experts have raised alarm that lack of financial assistance and guidance on technical expertise have marred pharma MSMEs’ prospects to comply with revised Schedule M guidelines of December 31, 2025.
2 mins
December 11, 2025
Listen
Translate
Change font size
